Five things for pharma marketers to know: Thursday, June 14, 2018

Share this content:

GlaxoSmithKline met its goal in late-stage studies for a two-drug HIV treatment. The combination is as effective as a combination of three drugs, reducing how many medicines patients may need to take. (Reuters)

The annual Party at BIO Not Associated with BIO (PABNAB) sparked controversy again this year. After seeing topless women dancing with logos from sponsors painted on their bodies, Kate Strayer-Benton, director of strategy at Momenta Pharmaceuticals, edited and recirculated a letter from 2016 that asked the industry to stop working with companies that throw parties like PABNAB. John Maraganore, chairman of the trade group that hosts BIO, said companies sponsoring PABNAB are no longer welcome at the event. (STAT)

Mylan received a complete response letter from the FDA for its generic version of Advair, a medicine for asthma. Mylan said there are minor deficiencies to resolve. The decision allows GSK to retain control of the market with Advair, as generics from Novartis and Hikma Pharmaceuticals have also been rejected recently. (Endpoints)

Fifty bills to combat the opioid crisis will have been considered by the House of Representatives by next week. The legislation has covered topics from better monitoring opioid prescriptions to supporting affected families. (STAT)

One-third of U.S. adults are unaware their prescription drugs may cause depression or an increased risk of suicide, according to a study. The research, conducted at the University of Illinois at Chicago, found many commonly used prescriptions with side effects do not have proper warning labels. (CNBC)

Share this content:
Scroll down to see the next article